Panel Discussion: Strategic Considerations for Clinical Success in Hidradenitis Suppurativa
Time: 9:30 am
day: Day Two
Details:
- Explore how leading developers are balancing the need for regulatory-aligned endpoints with endpoints that demonstrate value to payers and patients
- Debate strategies for designing more efficient trials through novel endpoint combinations and timing of assessments to accelerate development timelines
- Understand different approaches to generating compelling evidence packages that support both regulatory approval and market access in an increasingly competitive landscape
- Discuss how industry, academia, clinicians, patients, and regulators can cooperate to advance the state of HS treatment and deliver higher quality drugs to patients
